-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although patients with metastatic hormone-sensitive prostate cancer (mHSPC) can be treated with androgen deprivation therapy (ADT), metastases can still progress to anti-prostate cancer (mCRPC
Recently, researchers from South Korea published an article in Eur Urol Focus investigating the role
This prospective study included 75 patients with elevated prostate-specific antigens, analyzed their cell-free DNA (cfDNA) in pre-treatment plasma samples, and performed low-depth whole-genome sequencing of cfDNA to identify CNAs
Of the 22 IScore-positive patients, 86.
Different factors predict the development of castration resistance
Taken together, IScore can serve as a biomarker
Original Source:
Chung Un Lee, Eunhae Cho, Junnam Lee et al.